Are peptides legal now? What the October 2026 HHS change means for you

Short answer: some peptides just got easier to get with a prescription, but none of them became FDA-approved. On October 28, HHS released a draft policy saying it won't take action against licensed compounding pharmacies that make six peptides, including BPC-157.

If you've been reading the headlines and feeling more confused than before, that makes sense. For most of the past year, the message was "the FDA is cracking down." Now it's "access is opening up." Both are partly true. Here's what actually changed, what didn't, and how to think about it for yourself.

What HHS changed on October 28

HHS announced a draft, temporary policy called "enforcement discretion." In plain terms, HHS says it won't take action against state-licensed compounding pharmacies that make these six peptides for patients with a prescription:

• BPC-157

• TB-500

• KPV

• MOTS-c

• Epitalon

• Semax

The policy comes with conditions. Pharmacies have to certify the identity and purity of what they make, according to NBC News. They also have to report side effects, which wasn't required before. And the raw peptides must come from FDA-registered manufacturers, according to AP.

It's also narrower than the headlines suggest:

• One peptide per product. Blends, like BPC-157 mixed with TB-500, aren't covered.

• Set routes only. Semax is nasal only, KPV is topical or oral, and TB-500, MOTS-c and epitalon are injections only.

• Individual prescriptions only. It covers pharmacies filling a prescription for one patient, not large outsourcing facilities.

• State rules still apply. Your state's pharmacy board can set its own limits.

It's meant as a bridge. Ingredients that aren't part of an approved drug usually have to be on an official FDA list before pharmacies can compound with them. That's the 503A bulks list, explained here. Adding these six for good takes a formal rule, a public comment period and a final decision, which can take months or longer. The draft policy itself is published in the Federal Register on October 30, with public comments open for two weeks. In July, an FDA advisory committee narrowly voted to recommend the same six. We covered that in our look at the July review.

What didn't change

This is the part that's easy to miss. HHS said in a statement that the policy "does not grant FDA approval or establish clinical safety and effectiveness."

That means:

• None of these peptides is FDA-approved for any condition.

• The evidence in people is still thin. In documents for the July meeting, FDA reviewers said the BPC-157 studies were too small and too short to show safety or benefit. They found no human safety studies for KPV, TB-500, MOTS-c or epitalon.

• The safety questions are still open. In 2023, FDA flagged possible risks for BPC-157 and TB-500, including allergic reactions, kidney damage and tumor growth, according to AP.

• "Research chemical" peptides sold online are still not legal for human use. This policy covers pharmacies filling prescriptions, not websites selling vials. Here's how to tell the difference.

• It can change again. The policy is a temporary draft, and HHS said it may revisit it if safety or quality problems show up.

Why experts disagree

HHS frames the move as a safer alternative to the black market. The thinking: if people are going to use these peptides anyway, it's better that they come from a licensed U.S. pharmacy than from an unknown seller.

Many scientists and doctors aren't convinced. AP reported that most FDA scientific staff opposed the plan and had limited input in drafting it. The American Medical Association warned that the peptides haven't been through the testing FDA-approved drugs require. One of the FDA's long-standing concerns with injected peptides is how the immune system can react to them.

Both sides are pointing at real risks. Gray-market products are a genuine problem. So is using a drug in people before it's been properly studied in people. Holding both of those at once is a reasonable place to be.

Should you try one?

That depends on what you're hoping it will do, and whether something better studied could do it instead.

People often look into peptides for joint or tendon pain, gut problems, weight loss, recovery or aging. For several of those, there are FDA-approved treatments with years of human data behind them. For weight loss in particular, the peptide drugs with real trial results are GLP-1 medications like semaglutide and tirzepatide, not BPC-157. Here's how those compare.

If you're still interested in a compounded peptide, these questions are worth asking whoever prescribes it:

• What's the human evidence for this peptide, for my specific problem?

• Is there an FDA-approved option I should try first?

• Which pharmacy will make it, and is it state-licensed?

• What side effects should I watch for, and who do I call if I have one?

• What happens to my treatment if this policy ends?

A prescriber who answers those plainly is a good sign. Pressure to buy a package quickly, or vague answers about where the product comes from, is a reason to pause.

A clear read before you spend anything

Is it worth a few hundred dollars and a month of injections to find out a peptide doesn't help? You can get a plain-language read first. Ask Doctronic's medical AI what the evidence says for your situation, free and at any hour. If you want a prescription for an FDA-approved treatment, a licensed doctor is available by video for $39.

Doctronic doesn't prescribe compounded peptides. We'll help you understand your options and find the ones with the strongest evidence behind them.

For background on how FDA has handled each peptide, see our peptide FDA status tracker.

The Bottom Line

The October 2026 HHS draft policy makes six peptides easier to get through a licensed pharmacy with a prescription, but it doesn't make them FDA-approved or proven. If you're curious about a peptide, start by asking what it's meant to do for you and whether a better-studied option exists. Doctronic's medical AI can walk you through the evidence for free, any hour, and a licensed doctor is available by video for $39 to talk through FDA-approved treatments. This article is informational and is not a medical diagnosis.